Abstract:Background Anomalous activation of NF-κB signaling is associated with many inflammatory disorders, such as ulcerative colitis (UC) and acute lung injury (ALI). NF-κB activation requires the ubiquitination of receptor-interacting protein 1 (RIP1) and NF-κB essential modulator (NEMO). Therefore, inhibition of ubiquitation of RIP1 and NEMO may serve as a potential approach for inhibiting NF-κB activation and alleviating inflammatory disorders. Purpose Here, we identified arteannuin B (ATB), a sesquiterpene lactone found in the traditional Chinese medicine Artemisia annua that is used to treat malaria and inflammatory diseases, as a potent anti-inflammatory compound, and then characterized the putative mechanisms of its anti-inflammatory action. Methods Detections of inflammatory mediators and cytokines in LPS- or TNF-α-stimulated murine macrophages using RT-qPCR, ELISA, and western blotting , respectively. Western blotting, CETSA, DARTS, MST, gene knockdown, LC-MS/MS, and molecular docking were used to determine the potential target and molecular mechanism of ATB. The pharmacological effects of ATB were further evaluated in DSS-induced colitis and LPS-induced ALI in vivo . Results ATB effectively diminished the generation of NO and PGE 2 by down-regulating iNOS and COX2 expression, and decreased the mRNA expression and release of IL-1β, IL-6, and TNF-α in LPS-exposed RAW264.7 macrophages. The anti-inflammatory effect of ATB was further demonstrated in LPS-treated BMDMs and TNF-α-activated RAW264.7 cells. We further found that ATB obviously inhibited NF-κB activation induced by LPS or TNF-α in vitro . Moreover, compared with ATB, dihydroarteannuin B (DATB) which lost the unsaturated double bond, completely failed to repress LPS-induced NO release and NF-κB activation in vitro . Furthermore, UBE2D3, a ubiquitin-conjugating enzyme, was identified as the functional target of ATB, but not DATB. UBE2D3 knockdown significantly abolished ATB-mediated inhibition on LPS-induced NO production. Mechanistically, ATB could covalently bind to the catalytic cysteine 85 of UBE2D3, thereby inhibiting the function of UBE2D3 and preventing ubiquitination of RIP1 and NEMO. In vivo , ATB treatment exhibited robust protective effects against DSS-induced UC and LPS-induced ALI. Conclusion Our findings first demonstrated that ATB exerted anti-inflammatory functions by repression of NF-κB pathway via covalently binding to UBE2D3, and raised the possibility that ATB could be effective in the treatment of inflammatory diseases and other diseases associated with abnormal NF-κB activation.

The Anti-Malarial Artemisinin Inhibits Pro-Inflammatory Cytokines Via the NF-ÎºB Canonical Signaling Pathway in PMA-induced THP-1 Monocytes

Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways.

Artemisinin Inhibits Monocyte Adhesion to HUVECs Through the NF-κB and MAPK Pathways in Vitro.

Artemisinin Attenuates Lipopolysaccharide-Stimulated Proinflammatory Responses By Inhibiting Nf-Kappa B Pathway In Microglia Cells

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Anti-malarial artesunate ameliorates atherosclerosis by modulating arterial inflammatory responses via inhibiting the NF-κB–NLRP3 inflammasome pathway

Artemisinin Inhibits Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and Matrix Metalloproteinase‐9 Expression Via a Protein Kinase Cδ/p38/extracellular Signal‐regulated Kinase Pathway in Phorbol Myristate Acetate‐induced THP‐1 Macrophages

Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway

Anti-inflammatory effects of artesunate on atherosclerosis via miR-16-5p and TXNIP regulation of the NLRP3 inflammasome

Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells

Artemisinin suppresses sympathetic hyperinnervation following myocardial infarction via anti-inflammatory effects

Artemisinin attenuated atherosclerosis in high-fat diet-fed ApoE-/- mice by promoting macrophage autophagy via AMPK/mTOR/ULK1 pathway.

Artesunate inhibits LPS-induced production of TNF-α via inhibition of NF-κB signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes

Artesunate inhibits macrophage-like phenotype switching of vascular smooth muscle cells and attenuates vascular inflammatory injury in atherosclerosis via NLRP3

Pre-clinical studies comparing the anti-inflammatory potential of artemisinic compounds by targeting NFκB/TNF-α/NLRP3 and Nrf2/TRX pathways in Balb/C mice

Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms

Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway.

Artemisinin Protects Porcine Mammary Epithelial Cells Against Lipopolysaccharide-Induced Inflammatory Injury by Regulating the NF-κB and MAPK Signaling Pathways.

Artesunate Attenuated Progression of Atherosclerosis Lesion Formation Alone or Combined with Rosuvastatin Through Inhibition of Pro-Inflammatory Cytokines and Pro-Inflammatory Chemokines

Arteannuin B, a sesquiterpene lactone from Artemisia annua , attenuates inflammatory response by inhibiting the ubiquitin-conjugating enzyme UBE2D3-mediated NF-κB activation

Artemisinin Reduces Lipid Accumulation in Hepatocytes by Inhibition of CD36 Expression